

# Trading update

*13 July 2022*

# Disclaimer

The information contained in this presentation ("Presentation") has been prepared by Physiomics Plc (the "Company"). This Presentation has not been approved by an authorised person in accordance with Section 21 of the Financial Services and Markets Act 2000 ("FSMA"). This Presentation should not be considered as the giving of investment advice by the Company or any of its shareholders, directors, officers, agents, employees or advisers. Each party to whom this document is made available must make its own independent assessment of the Company after making such investigations and taking such advice as maybe deemed necessary. Any person who receives this Presentation should not rely or act upon it. Any person who is in any doubt about this Presentation should consult a person duly authorised for the purposes of FSMA who specialises in the acquisition of shares and other securities.

Whilst the information contained in this Presentation has been prepared in good faith, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers give, have given or have authority to give, any representations or warranties (express or implied) as to, or in relation to, the accuracy, reliability or completeness of the information in this Presentation, or any revision thereof, or of any other written or oral information made or to be made available to any interested party or its advisers (all such information being referred to as "Information") and liability therefore is expressly disclaimed. Accordingly, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers take any responsibility for, or will accept any liability whether direct or indirect, express or implied, contractual, tortious, statutory or otherwise, in respect of, the accuracy or completeness of the Information or for any of the opinions contained herein or for any errors, omissions or misstatements or for any loss, howsoever arising, from the use of this Presentation. All statements of opinion and/or belief contained in this Presentation and all views expressed represent the directors' own current assessment and interpretation of information available to them as at the date of this Presentation.

This Presentation has not been fully or independently verified and is subject to material updating, revision and further amendment. In furnishing this Presentation, the Company does not undertake or agree to any obligation to provide the recipient with access to any additional information or to update this Presentation or to correct any inaccuracies in, or omissions from, this Presentation which may become apparent.

This Presentation contains certain forward-looking statements that involve substantial risks and uncertainties, and actual results and developments may differ materially from those expressed or implied by these statements. These forward-looking statements include, but are not limited to, statements regarding the Company's intentions, beliefs or current expectations concerning, among other things, the Company's results of operations, financial condition, prospects, growth, forecasts, projections, strategies and the industry in which the Company operates. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Therefore, actual results and future events could differ materially from those anticipated in such statements. Risks and uncertainties that could cause results of future events to differ materially from current expectations expressed or implied by the forward-looking statements include, but are not limited to, loss of major customer(s), competition and pricing pressure, personnel and skills, requirements of additional financing risk, regulation changes, systems and infrastructure, the COVID-19 pandemic, and other risks. No representation is made or assurance given that such statements or views are correct or that the objectives of the Company will be achieved. The reader is cautioned not to place reliance on these statements or views and no responsibility is accepted by the Company or any of its shareholders, directors, officers, agents, employees or advisers in respect thereof.

This Presentation should not be considered as the giving of investment advice by the Company, or any of its shareholders, directors, officers, agents, employees or advisers in relation to the acquisition of shares in the Company. In particular, this Presentation does not constitute an offer or invitation to subscribe for or purchase any securities and neither this Presentation nor anything contained herein shall form the basis of any contract or commitment whatsoever.

Neither this Presentation nor any copy of it may be: (a) taken or transmitted into Australia, Canada, Japan, the Republic of Ireland, the Republic of South Africa or the United States of America (each a "Restricted Territory"), their territories or possessions; (b) distributed to any US person (as defined in Regulation S under the United States Securities Act of 1933 (as amended)); or (c) distributed to any individual outside a Restricted Territory who is a resident thereof, in any such case for the purpose of offer for sale or solicitation or invitation to buy or subscribe any securities or in the context where its distribution may be construed as such offer, solicitation or invitation, in any such case except in compliance with any applicable exemption. The distribution of this document in or to persons subject to other jurisdictions may be restricted by law, and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Any failure to comply with these restrictions may constitute a violation of the laws of the relevant jurisdiction.

By accepting receipt or attending any delivery of, or electronically accessing, this Presentation, each recipient agrees to be bound by the above limitations and conditions and, in particular represents, warrants and undertakes to the Company that: (i) they will not forward the Presentation to any other person, or reproduce or publish this document, in whole or in part, for any purpose; and (ii) they agree to comply with the contents of this notice.




# Physiomics is focused on modelling cancer



Knowledge of  
cancer

PK/ PD\* modelling  
Virtual Tumour™



Ability to access  
and curate data

Understanding of AI/  
machine learning






# We work with biotech/ pharma and develop personalised oncology tools

## Supporting oncology R&D



- Analytical and modelling support for oncology pre-clinical development



- **Virtual Tumour™** in-silico platform predicts tumour regression
- Focus on optimisation of combination regimes including immune-oncology, DNA damage & repair agents, radiation

## Personalised oncology




- Personalised dosing tool for docetaxel in prostate cancer
- Grant funded by Innovate UK and NIHR (i4i)
- Potential to predict individual toxicities
- Applications in clinical practice and trials
- Research agreement with TabulaRasa Healthcare/ DoseMeRx
- PARTNER trial ongoing



# We've completed over 80 commercial and grant funded projects

---







## How we support development

---

Recommend **efficacy/ toxicity** trade-offs



Recommend experiments to **confirm and refine hypotheses** if desired



Recommend **combination partner agent** for proprietary in-house asset



Assess efficacy of existing assets in **new indications**



Predict **biologically effective dose in humans** to support clinical translation



Help build **story** for investors/ partners






## Trading update

---

- Total income and profit after tax for the financial year ended 30 June 2022 is likely to be in-line with market expectations
- Investments in the year included the hiring of three new staff members (two technical and the new Head of Business Development) which contributed to net cash outflows of £356k
- Despite this, the Company's cash position remains strong, with £687k at the bank as at 30 June 2022, representing almost two years of cash runway assuming cash burn at current levels
- The Directors expect that the hiring of these key staff will translate to increased revenues during the financial year ending 30 June 2023
- During the financial year ended 30 June 2022 we signed new or follow-on business with Merck KGaA, Numab Therapeutics, Bicycle Therapeutics, Ankyra Therapeutics, Ducentis Biotherapeutics
- Since our interims presentation in March we have:
  - Signed a first project with French big pharma company, Servier
  - Retained Dr Tim Corn as highly experienced NED
- In addition, the Company has progressed its observational clinical trial in Portsmouth, designed to generate data to further validate and develop its personalised dosing software
- We note that on 30 June Valirx extended the exclusivity period for TheorumRx Inc to complete its financing and execute a sub-licence of VAL201



# Total income for financial year ended 30 June 2022



Source: Company full year and interim reports





## PARTNER study update

---

- Analysing interim data from ~24 patients for NIHR end of grant report
- Study will continue to recruit until September and a final analysis of data will be conducted in Q4 this calendar year
- We are particularly interested in the ability of the tool to:
  - Predict clinically relevant events (e.g. associated with chemo related toxicities)
  - Predict which patients might benefit from GCSF (granulocyte colony stimulating factor), an expensive drug used to boost white cell counts in patient undergoing chemo
- Next steps will be determined once the analysis is complete but could include:
  - Further development/ evolution of the current tool
  - Extending relationship with DoseMeRx
  - Further grant funded work to extend tool to other indications/ drugs



## Summary

---

- Performing per market expectations
- Good cash runway based on current burn rate
- Anticipate increased revenues in current financial year as a result of investments in technical and business development personnel
- Await with interest analysis of data from our PARTNER trial in Portsmouth
- Continuing to seek other opportunities to grown business

## Contacts:

- Physiomics plc, [info@physiomics.co.uk](mailto:info@physiomics.co.uk)
- Hybridan LLP, Broker, [research@hybridan.com](mailto:research@hybridan.com)



## Board of directors

---

- Dr Jim Millen (Executive Chairman & CEO) joined Physiomics in April 2016, bringing over 15 years' experience in pharmaceuticals and biotechnology gained at a number of blue-chip global companies as well as smaller UK-based organisations. At Allergan, Jim was responsible for corporate development in its Europe, Africa and Middle East region where he was pivotal in expanding the Company's geographical footprint before moving to a senior role responsible for commercial strategy and market access. Prior to that, at GSK, Jim held business development roles of increasing responsibility including within the Company's innovative Centre of Excellence for External Drug Discovery. Jim has also supported a number of smaller companies in fund raising and strategic partnering activities. Over the course of his career he has completed an array of deals worth many hundreds of millions of dollars, spanning licencing, acquisition, divestment, development and commercialisation. Jim studied medicine at Queens' College, Cambridge University and qualified as a doctor from the London Medical School. He holds an MBA from INSEAD. Jim's ability to develop and grow businesses and drive towards ambitious goals is of great value in his role as CEO.
- Dr Christophe Chassagnole (COO) has been involved in systems biology and bio-computing projects since the mid-nineties, with experience in both academic and industrial environments. His Doctorate was achieved at the Victor Segalen-Bordeaux II University, and then he held a post doctorate position with IBVT at Stuttgart University. Before joining Physiomics Dr Chassagnole worked in France as a senior researcher for CRITT Bio-Industries (Toulouse) for 3 years. He joined Physiomics in May 2004 as project leader to develop the model portfolio of the Company. He was appointed Chief Operating Officer of Physiomics in May 2007, in this capacity he has initiated and supervised the development of the Virtual Tumour™ technology. Christophe remains the main source of scientific knowledge on the biology of cancer and modelling/simulation as it relates to drug development. Christophe maintains his knowledge through regular literature reviews and is highly valued by clients for this reason. Christophe is also responsible for managing the Company's R&D activities and in particular of our initiative in personalized medicine.





## Board of directors

---

- Dr Tim Corn (Independent Non-Executive Director) Dr Tim Corn qualified in medicine at King's College Hospital and, after becoming honorary Consultant and Senior Lecturer, joined the pharmaceutical industry in 1983. He has held senior positions in both big and small pharma as well as at the MHRA and became CMO of several small but highly successful venture-backed companies, such as EUSA Pharma and Zeneus Pharma. He has played a key role in more than twenty regulatory approvals in the USA and Europe, is the author of more than forty scientific publications, and was elected Fellow of both the Faculty of Pharmaceutical Medicine and the Royal College of Psychiatrists. Tim currently serves as Trustee of Nerve Tumours UK, and as CMO of Nodenza Inc.